Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial

Australas Psychiatry. 2018 Feb;26(1):82-87. doi: 10.1177/1039856217726449. Epub 2017 Aug 24.

Abstract

Objectives: Depression is a mental disorder, affecting the quality of life. Our study explores the efficacy of Pranic Healing (PH), as an adjuvant therapy in treating depression Methods: In this randomised double-blind controlled trial, 52 participants with a mean age of 34.4 years, with mild to moderate depression were assessed using the Hamilton Depression Rating (HAM-D) scale during the 5-week study. Both Medication + PH (MedPH) and Medication + Mock PH (MedMockPH) groups comprising 26 members received Pranic and mock healing lasting 20 minutes per session respectively once a week for 4 weeks, along with the antidepressant drug.

Results: The average decrease in HAM-D score in MedPH was median 11 (Interquartile Range (IQR) 7-12) and was significantly higher compared with the MedMockPH group median 6.5 (IQR 3-9). At pre-assessment, both groups had 8 cases of mild and 18 cases of moderate depression. At post-assessment, HAM-D showed that the improvement in depression category was seen in 69.2% of participants in the MedMockPH group and 100% in MedPH group.

Conclusions: These results give first the evidence that PH can aid as an adjuvant therapy for depressed people.

Keywords: Prana; complementary therapy; depression; quality of life.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Citalopram / pharmacology
  • Combined Modality Therapy
  • Depression / drug therapy
  • Depression / therapy*
  • Depressive Disorder / drug therapy
  • Depressive Disorder / therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Medicine, Ayurvedic
  • Middle Aged
  • Mind-Body Therapies / methods*
  • Outcome Assessment, Health Care*
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Severity of Illness Index

Substances

  • Citalopram
  • Selective Serotonin Reuptake Inhibitors

Associated data

  • CTRI/CTRI/2015/08/006099